Chemical formula: C₂₁H₂₁F₃IN₃O₂ Molecular mass: 531.318 g/mol PubChem compound: 16222096
Cobimetinib is a reversible, selective, allosteric, oral inhibitor that blocks the mitogen-activated protein kinase (MAPK) pathway by targeting the mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK 2 which results in inhibition of phosphorylation of the extracellular signal-regulated kinase (ERK) 1 and ERK 2. Therefore, cobimetinib blocks the cell proliferation induced by the MAPK pathway through inhibition of the MEK1/2 signalling node.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EE02 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| COTELLIC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Cobimetinib is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Ecuador (EC)
Estonia (EE)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Lithuania (LT)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Singapore (SG)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
